SLC5A2 and diabetes mellitus: A multiple lines of experimental studies [17,20,21] on type 1 or type 2 diabetic animals show that glycemic control with SGLT2 inhibitors reduces the progression of diabetic nephropathy, one of the major microvascular complications attributable to diabetes.